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Abstract: Several studies have demonstrated the effectiveness of adjunctive antidepressant 
drug therapy to improve the depressive or negative symptoms of schizoaffective disorder, 
however, monotherapy with atypical antipsychotics may be advantageous. We compared the 
efﬁ  cacy and safety of risperidone monotherapy versus combination therapy of haloperidol with 
sertaline for the acute treatment of schizoaffective disorder, depressed type. This is an open label 
study of 52 female inpatients randomly assigned to risperidone alone (N = 26) or haloperidol in 
combination with sertraline (N = 26) for 12 weeks. The mean daily doses of medications were: 
risperidone: 3.75–3.29 mg/day, haloperidol: 5.35–4.15 mg/day, sertraline: 65.39–133.82 mg/day. 
Efﬁ  cacy was measured using clinical rating scales of treatment, safety, and tolerability. Risperi-
done patients showed statistically signiﬁ  cant greater improvement than haloperidol-sertraline 
patients on efﬁ  cacy measures including Positive and Negative Syndrome Scale and Clinical 
Global Impressions rating. A higher number of risperidone patients dropped out of the study 
early. Fewer adverse events and lesser need for concomitant medications occurred in patients 
on risperidone. The risperidone group showed better psychological, social and occupational 
functioning (Global Assessment of Functioning) and higher quality of life (Heinrich’s Quality 
of Life Scale). Risperidone has higher antipsychotic efﬁ  cacy and tolerability compared with 
haloperidol-sertraline combination for the acute treatment of schizoaffective disorder, depressed 
type. Both treatments were comparable in terms of antidepressant efﬁ  cacy.
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Introduction
The existence of schizoaffective disorder as a separate diagnostic entity has been 
the subject of debate.1–3 It has often been considered to be the “waste” basket of a 
diagnosis by exclusion. Nevertheless, the combination of schizophrenic and depres-
sive symptoms represents a clinical reality requiring accurate diagnosis and effective 
management. The prognosis of schizoaffective disorder is usually more favorable 
than for schizophrenia, but less positive in comparison to affective disorders.4 The 
depressed type of schizoaffective disorder represents a challenge due to the chronic 
and frequently deteriorating course of the illness with negative effects on all spheres 
of social functioning. The net result is higher utilization of health care resources.5,6 
A factor that can signiﬁ  cantly inﬂ  uence the prognosis for this disorder is the choice of 
suitable therapeutic strategy, in the acute, as well as the continuation and maintenance 
phases of treatment.
The pharmacotherapy of the acute phase of schizoaffective disorder involves 
primarily antipsychotic and secondarily antidepressant drugs. However, to achieve 
an optimal effect, patients with schizoaffective disorder, depressed type, require 
targeted pharmacologic therapy aimed at improving the schizophrenic as well as 
the affective components of the illness. Studies focusing on the pharmacotherapy of 
schizoaffective disorder, depressed type, are limited. Most studies have focused on Neuropsychiatric Disease and Treatment 2009:5 92
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the efﬁ  cacy and safety of antipsychotic monotherapy while 
opinions regarding the appropriateness of combined anti-
psychotic–antidepressant therapy vary. Antidepressants are 
especially useful when antipsychotic treatment improves the 
psychotic symptoms only.7
Due to their efﬁ  cacy and safety proﬁ  le atypical antipsy-
chotics should result in improved long-term efﬁ  cacy, quality 
of life, and patient compliance. Karow and colleagues8 
found a subjective preference for atypical antipsychotics by 
patients with schizophrenia and schizoaffective disorder, 
who had received long-term antipsychotic medication. As 
has been documented by Clark and colleagues,9 the use of 
atypical antipsychotics in patients with schizophrenia and 
schizoaffective disorder increased from 43% to 70% between 
1995 and 1999. However, a surprising ﬁ  nding of this study 
was that, in the era of new-generation antipsychotics with 
broad-spectrum efﬁ  cacy, combination antipsychotic therapy 
increased from 5.7% to 24.3%. In their meta-analysis of trials 
aimed at comparing long-term treatment with typical and 
atypical antipsychotics in patients with schizophrenia and 
schizoaffective disorder published between 1994 and 2005, 
Turner and Stewart10 observed a lower number of relapses, 
fewer adverse events (AEs) and higher efﬁ  cacy of atypical 
antipsychotics. Flynn and colleagues11 retrospectively studied 
therapy in 70 hospitalized patients with schizoaffective dis-
order (depressive symptoms present in 53% patients): 90% 
of patients received antipsychotics while the proportion of 
atypical antipsychotics increased year-to-year; 87% patients 
received an antipsychotic drug in combination with an anti-
depressant or mood stabilizer; only 6% of patients received 
monotherapy with a typical or atypical antipsychotic drug. 
There was a tendency to continue the antidepressant if the 
patient was receiving such treatment before hospitalization 
despite not currently experiencing depressive symptoms. The 
presence of depressive symptoms at the time of hospitaliza-
tion rarely leads to the administration of an antidepressant. 
Flynn and colleagues did not conﬁ  rm that monotherapy with 
atypical antipsychotics is a widespread method in clinical 
practice.
We had earlier conducted a retrospective pilot study to 
obtain an overview of current treatment strategies in the acute 
phase of treatment of schizoaffective disorder, depressed 
type.12 We determined that the most prevalent pharmaco-
therapeutic strategy was the combination of antipsychotics 
with antidepressants. The reasons for preferring such com-
bined treatment over monotherapy were: (a) low incidence 
of AEs with selective serotonin reuptake inhibitors (SSRIs) 
and serotonin–norepinephrine reuptake inhibitors (SNRIs), 
(b) statistically signiﬁ  cant effect on reduction of depressed 
symptoms, (c) decreased risk of relapse when changing the 
antipsychotic medication. The treatment of schizoaffective 
disorder in Slovakia was also studied by Dóci and colleagues13 
In this study, the combination of antipsychotics with antide-
pressants also prevailed over monotherapy with an antipsy-
chotic drug, while atypical antipsychotics were preferred.
The present 12-week study was designed to compare the 
efﬁ  cacy and safety of monotherapy with risperidone versus 
combination therapy with haloperidol and sertraline in the 
acute phase of schizoaffective disorder, depressed type.
Methods and materials
Study design
Open label, randomized, prospective, clinical study.
Inclusion and exclusion criteria
The study was meant to include men and women, aged 18–65, 
hospitalized for schizoaffective disorder, depressed type, 
diagnosed by ICD-10 criteria (The International Classiﬁ  ca-
tion of Diseases, 10th Revision) and DSM-IV (Diagnostic 
and Statistical Manual of Mental Disorders, 4th Edition). 
The nature of the episode was documented as ﬁ  rst or recur-
ring episode, relapse or gradual decompensation. The nega-
tive symptoms subscore had to be higher than the positive 
symptoms subscore (Positive and Negative Syndrome Scale 
[PANSS]) at the initial assessment. The total score on the 
Calgary Depression Scale for Schizophrenia (CDSS) had to 
be  5 at the initial assessment. Patients previously receiving 
a depot antipsychotic were included in the study only after 
a minimum of one therapeutic interval had lapsed. Women 
of reproductive age had to be practicing reliable contracep-
tion. The study was approved by the Institutional Ethics 
Committee and all patients had to give written informed con-
sent before enrolling in the study. Exclusion criteria included 
the presence of a mental disorder other than that speciﬁ  ed in 
the inclusion criteria, the need for electroconvulsive therapy, 
and a history of insufﬁ  cient efﬁ  cacy of the study medication. 
Patients with a serious or unstable medical condition were 
excluded; however, patients with a chronic illness who were 
stable on medication were allowed into the study.
Treatment
Risperidone monotherapy (Group R)
Risperidone was begun at 1 mg/day and subsequently titrated 
according to the condition of the patient. The mean daily dose 
of risperidone at week 1 was 3.75 mg/day (SD = 1.37) and at 
the end of week 12 it was 3.29 mg/day (SD = 1.51).Neuropsychiatric Disease and Treatment 2009:5 93
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Combined haloperidol and sertraline 
therapy (Group HS)
The initial dose of haloperidol was determined on the basis 
of the patient’s clinical condition. The initial dose of sertra-
line was 50 mg/day. The doses of combined therapy were 
individually and ﬂ  exibly adjusted. A low dose of haloperidol 
was preferred throughout the entire study. The mean daily 
dose of haloperidol at week 1 was 5.35 mg/day (SD = 3.97) 
and that of sertraline was 65.39 mg/day (SD = 23.53). At 
week 12 the mean daily dose of haloperidol was 4.15 mg/day 
(SD = 3.38) and the dose of sertraline was 133.82 mg/day 
(SD = 38.47). Anticholinergics, benzodiazepines, and non-
benzodiazepine hypnotics were allowed at the discretion of 
the physician and were recorded in the patient’s chart.
After obtaining informed consent, the patient’s eligibility 
for inclusion in the study was assessed. The patient then 
underwent an initial examination and was assigned a ran-
domized identiﬁ  cation code. A detailed record of previous 
psychotropic and nonpsychotropic medications was obtained. 
All psychotropic medications were discontinued and the 
study medication was initiated.
Assessment of psychopathology and efﬁ  cacy and safety 
of study medication were recorded at weeks 1, 2, and subse-
quently at two-week intervals. The ﬁ  nal assessment occurred 
after 12 weeks, or in case of an early drop-out, at the time of 
termination. All data were recorded in the patient’s chart. In 
case of an early drop-out, the reason was recorded as well.
Instruments for assessment of therapeutic efﬁ  cacy
•  Positive and Negative Syndromes Scale for Schizo-
phrenia (PANSS)14
•  Calgary Depression Scale for Schizophrenia (CDSS)15,16
•  Clinical Global Impression (CGI) (CGI-S; Severity of 
Illness, CGI-I; Improvement)17
•  Heinrich’s Quality of Life Scale (HQLS)18
•  Global Assessment of Functioning Scale (GAF)19
•  Drug Attitude Inventory (DAI)20
•  Patient Preference Scale (PPS)21
Instruments for assessment of treatment safety
•  Adverse events report (AER)
•  Simpson–Angus Extrapyramidal Symptoms Rating 
Scale (SAS)22
•  Laboratory tests, vital signs, body weight
Statistical analyses
The demographic and clinical variables are described 
based on characteristics of the study groups R and HS, and 
reciprocally compared using the Mann–Whitney U test and 
chi-square test. The characteristics of both groups were 
assessed separately for the baseline (week 0), end of study 
(week 12), and for the drop-out groups. The collected data 
represent quantiﬁ  able differences of grouped median scores 
of the assessment scales in respective assessed time points, 
which were analyzed using the method of “Observed Cases.” 
As the sets of patients are number-restricted, the statisti-
cal assessment applied nonparametric tests. For assessing 
statistical signiﬁ  cance, we applied the signiﬁ  cance level of 
at least 5% (p = 0.05). We placed emphasis on effect size, 
calculated as the correlation rate of effect size of difference 
between grouped medians (correlation rate rm). The correlation 
rate (effect size) is standardized, and reaches values from 0 
to 1. Its size will be interpreted as: 0.00–0.30 small, 0.30–0.50 
medium, over 0.50 large.
In the statistical evaluation of variance in scores and 
differences of scores in individual weeks in scales PANSS, 
CDSS, CGI-I, CGI-S, PPS, HQLS, DAI within each group, 
the Wilcoxon test (z) and the correlation rate of effect size 
between grouped medians (rm) were applied. The statistical 
evaluation of differences between individual groups and 
statistical evaluation of score variances in individual weeks 
used the Mann–Whitney U test and correlation rate of effect 
size between grouped medians (rm). The two-way signiﬁ  cance 
level (p) was evaluated. The interscale correlations within 
both groups and between the groups were assessed using 
correlation analysis. The primary indicator for evaluating 
the tightness of relation of two quantitative variables was 
determining the Spearman rank correlation coefﬁ  cient rho. 
The statistical software SPSS (SPSS Inc., Chicago, IL) and 
Excel 2000 (Microsoft Corp., Redmond, WA) were used 
for all analyses.
Results
Demographic and clinical characteristics 
of patients
Two thousand four hundred sixty-six patients were screened 
for the study. At the time of discharge from the hospital 
207 patients (32.9% male, 67.1% female) were diagnosed 
with schizoaffective disorder. Of these, 130 patients (62.8%) 
were treated for schizoaffective disorder, depressed type, and 
77 patients (37.2%) for manic type. None of the cases had 
the mixed type of schizoaffective disorder. The sex distri-
bution of patients with schizoaffective disorder, depressed 
type, was almost 4:1 in favour of females (78.5% female vs 
21.5% male) (Table 1).
When patient enrolment into the study was completed, 
54 patients (52 female) had met inclusion criteria. The only Neuropsychiatric Disease and Treatment 2009:5 94
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two male patients who met inclusion criteria dropped out 
at week 4, due to noncompliance with the study protocol. 
They were not included in the statistical analysis. The subject 
population included in the statistical analysis consisted of 
52 female patients, representing 2.1% of the initial group. 
The study patients were randomly assigned in a 1:1 ratio, 
either to the risperidone monotherapy (Group R) or to the 
haloperidol–sertraline combination therapy (Group HS). 
The randomization codes were assigned using the method of 
random number selection. The total duration of the study was 
12 weeks. All patients were hospitalized at the beginning of 
the study, and all were followed as outpatients after discharge 
from the inpatient service. Two patients were enrolled in 
the study at two different hospitalizations, after suffering a 
relapse three years later. A solid remission in both of these 
patients was obtained between hospitalizations. Since both 
patients were randomized at their second hospitalization and 
turned out to have been assigned to the other treatment group, 
they were kept in the data analysis.
Demographic and clinical characteristics of Groups R 
and HS at baseline are listed in Table 2. There were 14 drop-
outs in Group R and 9 dropouts in Group HS. There were 
no statistically signiﬁ  cant differences in demographic and 
clinical characteristics at weeks 0 and 12 (Mann–Whitney 
U test, chi-square test). Groups R and HS differed at week 
0 in living arrangement (rm = 0.47) and at week 12 in level 
of education (rm = 0.30) (Table 2).
Evaluation of therapeutic efﬁ  cacy
Positive and Negative Syndromes Scale 
for Schizophrenia
The subscore of positive and negative symptoms, the sub-
score of general psychopathology and the total PANSS score 
in Groups R and HS improved signiﬁ  cantly from week 0 
to week 12. In comparing Groups R and HS at week 0, a 
statistical signiﬁ  cance (p = 0.004) and medium effect size 
(rm = 0.39) was obtained only in the subscore of positive 
symptoms in favour of group R. At weeks 2 and 6, no statisti-
cally signiﬁ  cant differences in the total score and the PANSS 
subscores were obtained between the two Groups. At week 
6, the effect size of the total PANSS score (rm = 0.30) and 
the subscore of general psychopathology (rm = 0.32) suggest 
a signiﬁ  cant difference in favour of Group R. These differ-
ences gain statistical signiﬁ  cance and a large effect size at 
week 12 (rm = 0.47; rm = 0.56) (Figure 1).
Calgary Depression Scale for Schizophrenia
Improvement in depressive symptoms is demonstrated by the 
reduction in CDSS scores between weeks 0 and 12 in both 
groups. Group HS retained a higher CDSS score throughout 
the entire study. At the beginning of the study, the Groups 
differed signiﬁ  cantly (p = 0.001), reﬂ  ecting an effect of 
randomization, and the effect size was medium (rm = 0.46). 
To control for the signiﬁ  cant difference in baseline scores 
between the two groups, we also compared scores in weeks 
0–2, 2–6 and 6–12. During the course of the study the dif-
ference between Groups diminished slightly. At week 6, the 
difference was no longer statistically signiﬁ  cant (p = 0.136; 
rm = 0.23), however, it slightly increased again at week 
12 (p = 0.047; rm = 0.32) (Figure 2).
Clinical Global Impression
The severity of illness, as assessed by the CGI-severity 
(CGI-S) scale, decreased signiﬁ  cantly (p = 0.01) in both 
groups with a large effect size (rm   0.60). The severity 
of illness was comparable in both groups at the beginning 
(grouped medians: Group R: 5.06; Group HS: 5.46 points). 
At week 6, a statistically signiﬁ  cant difference (p = 0.048) 
and a medium effect size (rm = 0.32) in favor of Group R 
emerged, and from the perspective of effect size it persisted 
until week 12 (rm = 0.33). Clinical improvement assessed 
by CGI-I was statistically signiﬁ  cant with a large effect size 
in the course of the study in both groups. Improvement was 
more rapid during the ﬁ  rst six weeks.
Heinrich’s Quality of Life Scale
Both groups showed improvement in the quality of life 
(grouped medians: Group R: 23.44 vs 34.67 points; Group 
HS: 22.20 vs 31.33 points). There was no statistically sig-
niﬁ  cant difference and no effect size at the beginning of the 
study, however, Group HS achieved lower HQLS scores 
throughout the study. At the end of week 12, a medium 
Table 1 Population of patients with diagnosis F25.x according to 
ICD-10
Population of inpatients
in years 2003–2006 (n)
Number
2466
with diagnosis F25.x (n/%) 207/8.4%
F25.0 manic type (n/%) 77/37.2%
 Male 40/51.9%
 Female  37/48.1 
F25.1 depressed type (n/%) 130/62.8%
 Male 28/21.5%
 Female 102/78.5%
F25.2 mixed type (n/%) 0/0.0%
 Male 0/0.0%
 Female 0/0.0%Neuropsychiatric Disease and Treatment 2009:5 95
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effect size between Groups favoured Group R (r = 0.30) 
(Figure 3).
Global Assessment of Functioning Scale
Overall functioning in both groups improved signiﬁ  cantly 
during the study (p   0.001; rm   0.60). At week 0, groups 
did not differ signiﬁ  cantly and there was no effect size. 
The difference between groups grew during the study. 
At week 12 the difference became statistically signiﬁ  cant 
and there was a medium effect size in favor of Group R 
(p = 0.044; rm = 0.38) (Figure 4).
Drug Attitude Inventory
Patients’ attitude towards therapy showed a positive change 
during the study. In Group R, we noted an increase in DAI 
score from −4.29 at week 1 to 6.67 points at week 12. 
*
* *
**
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Figure 1 The grouped medians of Positive and Negative Syndrome Scale total scores at weeks 0, 2, 6, 12.
Notes: R Group R; HS Group HS; *p   0.05; **p   0.001; †rm   0.3; ‡rm   0.5. Wilcoxon test (z) and effect size (rm): Group R: week 0–2: z = −4.281; p   0.001; rm = 0.65; week 
0–6: z = −3.724; p   0.001; rm = 0.67; week 0–12: z = −3.062; p   0.001; rm = 0.68. Group HS: week 0–2: z = −4.398; p   0.001; rm = 0.66; week 0–6: z = −4.019; p   0.001; 
rm = 0.67; week 0–12: z = −3.622; p   0.001; rm = 0.67. Mann–Whitney U test (Z) and effect size (rm): Group R vs Group HS; week 0: 320.50; Z = −0.320; p = 0.754; rm = 0.04; 
week 2: 317.50; Z = −0.375; p = 713; rm = 0,05; week 6: 123.00; Z = −1.861; p = 0.063; rm = 0.30; week 12: 46.50; Z = −2.465; p = 0.012; rm = 0.47.
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Figure 2 The grouped medians of Calgary Depression Scale for Schizophrenia score at weeks 0, 2, 6, 12.
Notes: *p   0.05; **p   0.001; †rm   0.3. Wilcoxon test (z) and effect size (rm): Group R: week 0–2: z = −3.868; p   0.001; rm = 0.61; week 0–6: z = −3.969; p   0.001; 
rm = 0.66; week 0–12: z = −3.070; p   0.001; rm = 0.68. Group HS: week 0–2: z = −4.295; p   0.001; rm = 0.66; week 0–6: z = −4.021; p   0.001; rm = 0.67; t week 0–12: 
z = −3.626; p   0.001; rm = 0.67. Mann–Whitney U test (Z) and effect size (rm): Group R vs Group HS: week 0: 158.50; Z = −3.303; p = 0.001; rm = 0.46; week 2: 207.50; 
Z = −2.228; p = 0.025; rm = 0.32; week 6: 162.00; Z = –1.502; p = 0.136; rm = 0.23; week 12: 59.50; Z = −2.502; p = 0.047; rm = 0.32.Neuropsychiatric Disease and Treatment 2009:5 96
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In Group HS there was an increase from –0.75 to 7.56. The 
DAI score did not show any statistically signiﬁ  cant difference 
and no effect size between the two groups.
Patient Preference Scale
At week 0, Group R patients assessed their previous medi-
cation more positively, compared to patients in Group HS. 
Similarly at week 12, Group R patients showed higher 
preference for their study medication, compared to their 
previous medication. The rate of change of preference study 
algorithm, as compared to previous therapy, was comparable 
in both groups (+2 points).
Duration of hospitalization
There was no statistically signiﬁ  cant difference and no effect 
size in the duration of hospitalization in all patients, who 
23.44
34.67
22.20
31.33
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Week 12 Week 0
Group R Group HS
Figure 3 The grouped medians of Heinrich’s Quality of Life Scale score at weeks 0 and 12.
Notes: †rm 0.3. Wilcoxon test (z) and effect size (rm): Group R: week 0–12: z = −3.063; p   0.001; rm = 0.68. Group HS: week 0–12: z = −3.66; p   0.001; rm = 0.65. 
Mann–Whitney U test (Z) and effect size (rm): Group R vs Group HS: week 0: 290.00; Z = −0.881; p = 0.384; rm = 0.12; week 12: 66.50; Z = −1.576; p = 0.119; rm = 0.30.
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Figure 4 The grouped medians of Global Assessment of Functioning score at weeks 0, 6, and 12.
Notes: *p   0.05; †rm   0.3. Wilcoxon test (z) and effect size (rm): Group R: week 0–6: z = −3.523; p   0.001; rm = 0.65; week 0–12: z = −3.068; p   0.001; rm = 0.68. Group 
HS: week 0–6: z = −4.026; p   0.001; rm = 0.67; week 0–12: z = −3.635; p   0.001; rm = 0.67. Mann–Whitney U test (Z) and effect size (rm): Group R vs Group HS: week 0: 
327.00; Z = −0.203; p = 0.844; rm = 0.03; week 6: 142.00; Z = −1.343; p = 0.183; rm = 0.22; week 12: 57.00; Z = −2.015; p = 0.044; rm = 0.38.Neuropsychiatric Disease and Treatment 2009:5 97
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completed the study (grouped medians: Group R: 39.00 days; 
Group HS: 40.00 days).
Assessment of treatment safety
Adverse events reporting
Spontaneous AEs were recorded throughout the study. The 
most frequently reported AEs were related to the extrapyra-
midal syndrome (EPS); sedation and blurred vision occurred 
rarely. A decrease in the number of AEs was noted during 
the study, especially in Group R.
Simpson–Angus Extrapyramidal Symptoms 
Rating Scale
Extrapyramidal symptoms were rated with the SAS scale. 
Since they were mild in intensity, we simply recorded their 
presence or absence, without assigning a numerical score. At 
week 0, EPS in Group R occurred in 65.4% patients and in 
Group HS in 69.2% patients. These high EPS rates at baseline 
were due to the medications the patients were receiving previ-
ously as outpatients when we had no possibility to intervene. 
However, the intensity of the symptoms was very mild. At 
week 12, EPS occurred more frequently in Group HS, com-
pared to Group R (52.9% vs 33.3%), but this difference did 
not reach statistical signiﬁ  cance (p = 0.324).
Concomitant psychotropic medication
There was high need for concomitant psychotropic medi-
cation in both Groups. In Group R, the medication most 
frequently used at week 1 was benzodiazepine anxiolytics 
(65.4%) and nonbenzodiazepine hypnotics (50%). At weeks 
6 and 12, the most frequent need was for nonbenzodiazepine 
hypnotics and antiparkinsonians, identically 50% for each 
group of drugs (Figure 5).
The most frequently indicated drugs in Group HS at 
weeks 1 and 12 were antiparkinsonians (80.8%; 76.5%). 
The administration of benzodiazepine anxiolytics (65.4%) 
and non-benzodiazepine hypnotics (46.2%) was comparable 
to Group R (Figure 6).
Laboratory tests, vital signs, and body weight
Comparison of laboratory tests from week 0 to week 12 did 
not reveal any signiﬁ  cant differences. Blood pressure and 
pulse frequency were within normal limits throughout the 
study. No signiﬁ  cant weight change was observed in any 
of the groups.
Drop-out analysis
Fourteen patients of Group R and 9 patients of Group 
HS dropped out of the study earlier, for different reasons 
(Table 3).
Correlations between rating scales
In both groups we observed a positive correlation between 
CGI-S score and negative subscore, the subscore of general 
psychopathology, and total PANSS score, thus the decrease 
of schizophrenic symptoms was accompanied by a decrease in 
65.4%
15.4%
11.1%
8.3%
50.0% 50.0% 50.0% 50.0% 50.0%
38.9%
16.7% 16.7% 16.7%
30.8%
7.7%
0%
20%
40%
60%
80%
100%
Week 12 Week 6 Week 1
ANX-BZD HYP-BZD HYP-NON AP without 
Figure 5 Concomitant psychotropic medication in Group R.
Abbreviations: ANX-BZD, benzodiazepine anxiolytics; HYP-BZD, benzodiazepine hypnotics; HYP-NON, nonbenzodiazepine hypnotics; AP, antiparkinsonians.Neuropsychiatric Disease and Treatment 2009:5 98
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disease severity. In Group R we found a negative correlation 
between CDSS and HQLS scores, ie, the decrease of schizo-
phrenic symptoms was followed by an increase in patient’s 
quality of life. This positive correlation between the negative 
PANSS subscore and quality of life was established in Group 
HS. In Group HS the remission of schizophrenic and depres-
sive symptoms correlated with the improvement in disease 
severity, better subject attitude toward medication, netter qual-
ity of life and higher psychosocial functioning (Table 4).
Discussion
To the best of our knowledge, this is the ﬁ  rst head to head 
comparison of the efﬁ  cacy and safety of monotherapy with 
an atypical antipsychotic, risperidone, versus combination 
therapy using a typical antipsychotic, haloperidol, and a 
SSRI antidepressant, sertraline. Our results conﬁ  rm that 
both therapeutic strategies are effective in the treatment of 
schizoaffective disorder, depressed type. However, when 
comparing the two treatments, we obtained statistically sig-
niﬁ  cant differences and a positive effect size favouring the 
efﬁ  cacy and safety of risperidone monotherapy for the acute 
treatment of schizoaffective disorder, depressed type.
We conﬁ  rmed our hypothesis that risperidone mono-
therapy would be more efﬁ  cacious than combination therapy 
with haloperidol and sertraline for improving schizophrenic 
symptomatology and overall disease severity. However, we 
observed a comparable effect of both therapeutic regimens 
on negative schizophrenic and depressive symptoms and on 
their rate of global clinical improvement. Comparisons of the 
efﬁ  cacy of haloperidol and risperidone in improving negative 
symptoms have appeared in several publications.23–26 Judging 
from those reports, the efﬁ  cacy of risperidone versus haloper-
idol in patients with schizophrenic disorders with depressive 
symptoms is an unresolved question. In our study, the com-
parison included another factor, sertraline, an antidepressant 
extending the effect of haloperidol on affective symptoms, 
but concurrently represented a certain risk for potential 
drug interactions and possible worsening of schizophrenic 
symptoms. Müller-Siecheneder and colleagues27 compared 
the efﬁ  cacy of haloperidol and amitriptyline therapy to the 
efﬁ  cacy of risperidone in 123 patients with combination of 
psychotic and depressive symptoms in a six-week study. 
They observed a higher efficacy of combined therapy, 
although it was more frequently accompanied by AEs. The 
limitation of their study was the inclusion of patients with 
a combination of psychotic and depressive symptoms, and 
inclusion of psychotic depression.
With respect to quality of life and overall psychosocial 
functioning, our groups did not differ signiﬁ  cantly at week 0. 
Quality of life and overall functioning improved in both 
groups, however, more signiﬁ  cantly in Group R. Despite 
this ﬁ  nding, we would have expected more robust differ-
ences between the groups. Tempier and Pawliuk28 in their 
retrospective cross-study analysis did not observe better 
quality of life in patients taking atypical antipsychotics than 
in patients treated with typical antipsychotics. These authors 
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Figure 6 Concomitant psychotropic medication in Group HS.
Abbreviations: ANX-BZD, benzodiazepine anxiolytics; HYP-BZD, benzodiazepine hypnotics; HYP-NON, nonbenzodiazepine hypnotics; AP, antiparkinsonians.Neuropsychiatric Disease and Treatment 2009:5 99
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interpreted their results by assuming that higher demands are 
placed on the life of patients taking atypical antipsychotics 
than in those receiving typical antipsychotics.
In both groups we observed a comparable effect size and 
a positive change of patient attitude toward study medication 
(DAI scale). They not only had a better attitude toward study 
medication, as compared to their previous medication, but 
their attitude improved during the course of the trial. The 
positive change of attitude was particularly evident during 
the ﬁ  rst six weeks but levelled off between week 6 and 12 
in both groups. A likely explanation for this observation is 
that patients in an acute condition require relief during the 
ﬁ  rst few weeks of treatment, and efﬁ  cacious medication 
provides this relief. However, once the acute phase is over, 
the patient begins to consider the likely need for long-term 
therapy and becomes more concerned about the presence of 
adverse events. A more favorable assessment of the study 
medication in both groups, compared to the previous medi-
cation, was obtained with the PPS scale. In comparing the 
PPS scores at week 12, Group R patients (n = 12) evaluated 
the study medication more favorably than patients in Group 
HS (n = 17). This is in accord with our hypothesis and the 
results of published studies.8,29
Table 2 Demographic and clinical characteristics of Groups R, HS and drop-outs R and HS
Week 0 Week 12 Drop-outs
Group
Number (n)
R
26
HS
26
R
12
HS
17
R
14
HS
9
Age (years)
 Mean
 SD
 Grouped  median
 Range
41.92
13.08
43.00
19–65
44.92
10.40
47.67
20–61
42.92
11.48
41.67
24–65
44.94
10.92
48.00
20–61
41.07
14.68
45.00
19–60
44.89
9.98
46.00
29–57
Living arrangement (n/%)
 Alone
 With  partner
6/23.08%
20/76.92%
5/19.23%
21/80.77%
2/16.67%
10/83.33%
4/23.53%
13/76.47%
4/28.57%
10/71.43%
1/11.11%
8/88.89%
Level of education (n/%)
 Elementary  school
  High school without graduation
  High school with graduation
 Baccalaureate
 University
3/11.54%
4/15.38%
11/42.31%
2/7.69%
6/23.08%
2/7.69%
7/26.92%
9/34.62%
1/3.85%
7/26.92%
1/8.33%
1/8.33%
4/33.33%
2/16.67%
4/33.33%
2/11.76%
5/29.41%
5/29.41%
1/5.88%
4/23.53%
2/14.29%
3/21.43%
7/50.00%
0/0.00%
2/14.29%
0/0.00%
2/22.22%
4/44.45%
0/0.00%
3/33.33%
Employment (n/%)
 Student
 Unemployed
 Employed
 Invalid  pensioner
 Pensioner
1/3.85%
7/26.92%
6/23.08%
10/38.46%
2/7.69%
1/3.85%
2/7.69%
6/23.08%
14/53.85%
3/11.54%
1/8.33%
2/16.67%
4/33.33%
4/33.33%
1/8.33%
1/8.33%
2/11.76%
4/23.53%
8/47.06%
2/11.76%
0/0.00%
5/35.71%
2/14.29%
6/42.86%
1/7.14%
0/0.00%
0/0.00%
2/22.22%
6/66.67%
1/11.11%
Duration of disorder (years)
 Mean
 SD
 Grouped  median
 Range
12.18
11.46
8.33
0–39
10.90
9.48
7.50
0.5–36
11.00
9.22
9.00
0–26
10.03
9.05
6.20
0.5–29
13.20
13.35
6.00
0.25–39
12.56
10.60
10.00
1–16
Course of disorder (n/%)
  Episodic with progressive defect
  Episodic with remissions
17/65.38%
9/34.62%
19/73.08%
7/26.92%
6/50.00%
6/50.00%
13/76.47%
4/23.53%
11/78.57%
3/21.43%
6/66.67%
3/33.33%
Polarity of schizoaffective disorder (n/%)
  Unipolar – depressed
  Bipolar – depressed
15/57.69%
11/42.31%
20/76.92%
6/23.08%
7/58.33%
5/41.67%
13/76.47%
4/23.53%
8/57.14%
6/42.86%
7/77.78%
2/22.22%
Table 3 The reasons for drop-outs
Week 2 Week 4 Week 6 Week 8
Group R HS R HS R HS R HS
Number (n) 6 4 2 1 4 4 2 0
Reason
Low efﬁ  cacy 4 3 1 0 1 2 1 0
Adverse events 1 0 1 1 0 0 0 0
Mania 1 1 0 0 0 0 0 0
Noncompliance 0 0 0 0 3 2 1 0Neuropsychiatric Disease and Treatment 2009:5 100
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We did not validate our hypothesis that the mean duration 
of hospitalization would be shorter with risperidone therapy. 
Our results agree with the retrospective study of Flynn and 
colleagues11 who failed to observe a relationship between 
duration of hospitalization and type of treatment for schizoaf-
fective disorder, but who did establish a correlation between 
duration of illness and rate of improvement. With a longer 
history of schizoaffective disorder, the patient’s condition 
stabilized faster and required a shorter hospitalization. We 
did not examine this relationship in the present study.
We assessed the safety of therapy by the incidence of 
AEs and the need for concomitant medication. Generally, 
the incidence of AEs was low with both treatment strategies. 
The AEs, which we observed using the SAS scale, and those 
spontaneously reported, belong primarily to the EPS spec-
trum. A decrease in the intensity of AEs was observed during 
the study, especially in Group R. Reduction of antipsychotic 
dose and administration of concomitant medication had a 
positive effect on AEs. The need for concomitant psychotropic 
medication was high in both Groups. The administration of 
concomitant medication at the beginning of study was justiﬁ  ed 
by the need for symptom relief, such as insomnia, inner tension 
and anxiety. Generally higher doses of drugs are used at the 
beginning of antipsychotic therapy with treatment emergent 
AEs and the associated need for concomitant medication. Over-
all Group R showed lower need for concomitant medication 
than Group HS. No AEs were noted in vital signs, weight or 
laboratory measures in conjunction with either drug regimen.
The diagnosis of schizoaffective disorder, depressed type, 
has been the subject of many scientiﬁ  c discussions. The litera-
ture has been addressing it since its initial description and to the 
present day, as it is considered to be an ambiguous diagnostic 
entity. Many authors consider it to be a waste basket of diag-
noses. In attempting to diagnose the disorder accurately, we 
applied ICD-10 and DSM-IV criteria. The diagnostic process 
comprised three independent phases. Firstly, the admitting 
psychiatrist made the diagnosis at the time of hospitalization. 
Secondly, the diagnosis had to be conﬁ  rmed by the inpatient 
psychiatrist in charge of the patient while in the hospital. 
Thirdly, the psychiatric investigator conﬁ  rmed the diagnosis and 
determined eligibility of the patient to be enrolled in the study 
based on the inclusion and exclusion criteria. Thus, we are satis-
ﬁ  ed that the patient cohort was diagnostically homogeneous.
The present study has a number of limitations. One of them 
is the somewhat low number of patients in the two groups. 
Due to our rigorous inclusion and exclusion criteria, the target 
population was relatively small. At the time the study was con-
ducted, a total of 130 patients diagnosed with schizoaffective 
disorder, depressed type, were hospitalized. Of these, 41.5% 
met study criteria and signed informed consent. Schizoaffec-
tive disorder afﬂ  icts both sexes, however, it occurs far more 
frequently in women. The uneven sex distribution was sup-
ported by our study with predominant representation of female 
(n = 102) versus male (n = 28) patients. Ultimately, the entire 
study cohort analyzed consisted of female patients. Another 
limitation was the open design of the study reﬂ  ecting a possible 
subjective bias. This weakness, however, was partially offset 
by the advantage of enabling the patient to work psychoedu-
cationally with the treatment team and thereby improving the 
therapeutic relationship. In spite of these limitations, however, 
the data clearly established a signiﬁ  cant therapeutic advantage 
of monotherapy with the atypical antipsychotic, risperidone.
Conclusions
The study demonstrated higher efﬁ  cacy of risperidone mono-
therapy compared to combination therapy with haloperidol 
Table 4 Correlation analysis of scales
Group R (n = 12)
Dependent variables Spearman rank 
correlation 
coefﬁ  cient “rho”
PANSS negative subscore CGI-S 0.681*
PANSS general psychopathology CGI-S 0.739**
PANSS total score CGI-S 0.717**
CDSS HQLS −0.696*
Group HS (n = 17)
Dependent variables Spearman rank 
correlation 
coefﬁ  cient “rho”
PANSS negative subscore HQLS −0.638**
PANSS negative subscore GAF −0.497*
PANSS negative subscore CGI-S 0.718**
PANSS general psychopathology CGI-S 0.548*
PANSS general psychopathology DAI −0.709**
PANSS total score CGI-S 0.658**
PANSS total score GAF −0.535
PANSS total score DAI −0.584*
CDSS DAI −0.544*
CDSS CGI-S 0.485*
CDSS CGI-I 0.519*
HQLS CGI-S 0.550*
GAF DAI 0.513*
Notes: *p   0.05; **p   0.01.
Abbreviations: CDSS, Calgary Depression Scale for Schizophrenia; CGI-S, Clinical 
Global Impression-Severity; DAI, Drug Attitude Inventory; GAF, Global Assessment 
of Functioning; HQLS, Heinrich’s Quality of Life Scale; PANSS, Positive and Negative 
Syndromes Scale for Schizophrenia.Neuropsychiatric Disease and Treatment 2009:5 101
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and sertraline, in regards to schizophrenic symptomatology, 
but suggested comparable efﬁ  cacy in regards to depressive 
symptomatology for the acute treatment of schizoaffec-
tive disorder, depressed type. Risperidone monotherapy 
was more efﬁ  cacious in improving quality of life and psy-
chosocial functioning along with a more positive patient 
attitude toward therapy. Fewer adverse events and a lower 
need for concomitant medication in the risperidone group 
enhanced the patient’s quality of life and decreased the 
pharmacoeconomic impact of therapy overall. For these 
reasons risperidone monotherapy may be advantageous for 
long-term administration. On the other hand, combination 
of haloperidol and sertraline represents a highly effective 
therapeutic alternative, especially suitable for patients who 
may not tolerate risperidone. A distinct advantage of the 
combination is the beneﬁ  cial effect on depressive symptoms, 
which may represent an indication for such a regimen, if the 
affective component of this disorder predominates.
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